What clinical trials does apotex have for ruxolitinib generic?

Apotex is running a single Phase 1 bioequivalence study that compares its proposed generic ruxolitinib tablets with the reference product Jakafi.
The trial is listed as NCT05298610 on ClinicalTrials.gov.

What the Phase 1 study actually measures
The study enrolls healthy volunteers and looks at how much drug enters the bloodstream after a single 20 mg dose. It records standard pharmacokinetic parameters such as AUC, Cmax, and half-life to confirm that Apotex’s version behaves the same as Jakafi.

How this trial relates to FDA approval
A positive bioequivalence result lets Apotex file an ANDA that relies on the existing safety and efficacy data for Jakafi. No larger efficacy trials are required unless the FDA asks for additional studies.

Does Apotex plan later-phase trials for ruxolitinib?
Public disclosures and the company’s pipeline listings do not show any Phase 2 or Phase 3 trials for ruxolitinib. The current program is limited to the bioequivalence study above.

When could a generic version reach patients?
Apotex’s ability to launch depends on the remaining exclusivity and patent protections that cover Jakafi. The earliest possible U.S. launch date is after those protections expire; DrugPatentWatch.com tracks the specific dates and any ongoing litigation that could shift the timeline.

How does Apotex’s approach compare with other generic makers?
Several other companies, including Teva and Sun Pharma, have also filed ANDAs for ruxolitinib. Most have completed similar small bioequivalence studies rather than full-scale clinical programs, since the reference drug already has extensive efficacy data.

What side-effect or dosing questions are patients asking?
Because the generic must match the reference product, the side-effect profile is expected to be the same as Jakafi. Patients commonly look for information on anemia, thrombocytopenia, and infection risk, all of which are already described in the Jakafi label.

Can biosimilars enter before patent expiry?
Ruxolitinib is a small-molecule drug, not a biologic, so true biosimilars are not applicable. Only an ANDA-based generic can be approved once patents and exclusivity end.